NCR Online Journal

Scleroderma Pipeline Drugs and Companies Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

 Breaking News
  • No posts were found

Scleroderma Pipeline Drugs and Companies Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

January 11
17:46 2022
Scleroderma Pipeline Drugs and Companies Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments
Scleroderma Pipeline

DelveInsight’s Scleroderma Pipeline Insights report lays down a holistic coverage of the available therapies, Scleroderma pipeline therapies in different developmental phases of clinical trials, key companies active in the Scleroderma pipeline domain, driving factors and restraints in the commercial launch of the Scleroderma pipeline therapies, and future trends. 

 

Some of the key highlights from the Scleroderma Pipeline report:

  • DelveInsight’s analysis depicts a robust Scleroderma Pipeline with 50+ active players in the domain working on 50+ pipeline therapies
  • Key Scleroderma pipeline therapies such as Lenabasum, EHP 101, FT011, Belumosudil, Guselkumab, ECCS 50, KHK4827, SAR156597, Treprostinil, HZN-825, GS-248, Brentuximab Vedotin, C21, ARG201, Belumosudil, CAM2043, Tofacitinib, Sarilumab, FCX 013, VIB7734, AVID200 and others are under evaluation in different phases of clinical trials for the treatment of Scleroderma. 
  • Corbus Pharmaceuticals, Emerald Health Pharmaceuticals, Gesynta Pharma, Formation Biologics, Fibrocell Science, CSL Behring, ChemomAb, Luminary Therapeutics, Certa Therapeutics, Kadmon Corporation, Janssen Pharmaceutical, Horizon Therapeutics, Acceleron Pharma, Tvardi Therapeutics, BriaCell Therapeutics, Blade Therapeutics, Biosplice Therapeutics, AnaMar, Immunemed, Viela Bio among several others are key prominent pharma companies working in the domain. 
  • In January 2021, Timber Pharmaceuticals received Orphan Drug Designation from U.S. FDA for TMB-003 for the Treatment of Systemic Sclerosis.
  • CiVi 030 is an intravenous formulation of iloprost, a potent vasodilator and platelet inhibitor with anti-inflammatory and anti-fibrotic effects being developed for the treatment of digital ischemic episodes in people with Systemic Sclerosis (SSc). CiVi 030 received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for the treatment of Systemic Sclerosis (SSc).
  • In April 2020, Horizon Therapeutics announced that it had acquired Curzion Pharmaceuticals and its development-stage oral selective lysophosphatidic acid 1 receptor (LPAR1) antagonist, CZN001 (renamed HZN-825), for the treatment of Systemic Sclerosis.
  • FCX-013 is being developed as a disease-modifying, autologous cell-based gene therapy that utilizes lentiviral vectors to deliver functional matrix metalloproteinase 1 genes (MMP-1) to patients with moderate to severe localized Scleroderma.
  • The U. S. Food and Drug Administration has granted Orphan Drug designation to FCX-013 for the treatment of localized Scleroderma. In addition, FCX-013 has been granted Rare Pediatric Disease designation and Fast Track designation for the treatment of moderate to severe localized Scleroderma.

 

Request for Sample to know which pharma company is expected to be at the forefront in the coming years @ Scleroderma Emerging Therapies and Forecast 

 

The Scleroderma Pipeline report comprises detailed information on ongoing clinical trials, deals, mergers & acquisitions taking place in the domain, recent approvals and failures in space, and growth prospects across the Scleroderma domain.

 

Scleroderma Overview

Scleroderma is a group of rare diseases that leads to the hardening and tightening of the skin and connective tissues. There are 2 major types of Scleroderma: Localized Scleroderma that affects the skin and Systemic Scleroderma that affects blood circulation and internal organs as well as the skin. The condition appears to affect women more as compared to men. At present, there exists no cure for the disease; however, there are symptomatic treatment approaches available. 

 

Discover more about the disease, treatments, and pipeline therapies @ Scleroderma Pipeline Assessment 

 

Scleroderma Pipeline Drugs 

Drug

Company

Phase

MoA

RoA

Lenabasum

Corbus Pharmaceuticals

III

Cannabinoid receptor CB2 agonists

Oral

Iloprost

Eicos Sciences

III

Epoprostenol agonists

Intravenous

KHK4827

Kyowa Kirin

III

Interleukin 17 receptor antagonists

Subcutaneous

ECCS-50

Cytori therapeutics

III

Cell replacements

Subcutaneous

EHP 101

Emerald Health Pharmaceuticals

II

Cannabinoid receptor CB2 agonists; Endothelial PAS domain-containing protein 1 inhibitors; Hypoxia-inducible factor 1 inhibitors; Peroxisome proliferator-activated receptor-gamma agonists

Oral

FT011

Certa Therapeutics

II

Platelet-derived growth factor inhibitors

Oral

Belumosudil

Kadmon Corporation

II

Rho-associated kinase inhibitors

Oral

Guselkumab

Janssen Pharmaceutical

II

Interleukin-23 subunit p19 inhibitors

Intravenous, Subcutaneous

FCX 013

Castle Creek Biosciences

I/II

Gene transference; Matrix metalloproteinase 1 replacements

Intradermal

VIB7734

Viela Bio

I

Dendritic cell inhibitors

NA

CM-101

Chemomab Therapeutics

I

Chemokine CCL24 inhibitors

Intravenous

AM1476

AnaMar

I

Serotonin 2B receptor antagonists

Oral

LMY-920

Luminary Therapeutics

Preclinical

Immunologic cytotoxicity; T lymphocyte replacements

Parenteral

CAN-10

Cantargia

Preclinical 

Interleukin 1 inhibitors; Interleukin-33 inhibitors

NA

hzVSF v13

ImmuneMed

Discovery

Immunomodulators; Virus replication inhibitors

NA

 

Request for Sample to know more @ Scleroderma Pipeline Analysis, Key Companies, and Futuristic Trends 

 

Scleroderma Therapeutics Assessment 

The Scleroderma Pipeline report proffers an integral view of the Scleroderma emerging novel therapies segmented by Stage, Product Type, Route of Administration, Molecule Type, Target, and Mechanism of Action.

By Product Type

  • Mono
  • Combination

By Stage

  • Discovery 
  • Pre-clinical
  • Phase I
  • Phase II
  • Phase III

By Molecule Type 

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy

By Route of Administration

  • Oral
  • Parenteral
  • Subcutaneous
  • Intravenous
  • Intradermal
  • Topical

By Mechanism of Action

  • Collagen inhibitors; Cytokine inhibitors
  • Dendritic cell inhibitors
  • Serotonin 2B receptor antagonists
  • Chemokine CCL24 inhibitors
  • Platelet-derived growth factor inhibitors
  • Gene transference; Matrix metalloproteinase 1 replacement
  • Cell replacements
  • Interleukin 1 inhibitors; Interleukin-33 inhibitors

By Targets

  • Proteins
  • Replication pathways

 

Scope of the Scleroderma Drug Pipeline Report

Coverage: Global

Key Players: Corbus Pharmaceuticals, Emerald Health Pharmaceuticals, Gesynta Pharma, Formation Biologics, Fibrocell Science, CSL Behring, ChemomAb, Luminary Therapeutics, Certa Therapeutics, Kadmon Corporation, Janssen Pharmaceutical, Horizon Therapeutics, Acceleron Pharma, Tvardi Therapeutics, BriaCell Therapeutics, Blade Therapeutics, Biosplice Therapeutics, AnaMar, Immunemed, Viela Bio among others.

Key Scleroderma Pipeline Therapies: Lenabasum, EHP 101, FT011, Belumosudil, Guselkumab, ECCS 50, KHK4827, SAR156597, Treprostinil, HZN-825, GS-248, Brentuximab Vedotin, C21, ARG201, Belumosudil, CAM2043, Tofacitinib, Sarilumab, FCX 013, VIB7734, AVID200 and several others. 

 

 

Table of Contents 

1

Report Introduction

2

Executive Summary

3

Scleroderma Disease Overview

4

Scleroderma Pipeline Therapeutics Comparative Analysis

5

Scleroderma Therapeutic Assessment

6

In-depth Commercial Assessment

7

Scleroderma – DelveInsight’s Analytical Perspective

8

In-depth Commercial Scleroderma Assessment

9

Scleroderma Collaboration Deals 

10

Late Stage Scleroderma Products (Phase III)

10.1

Lenabasum: Corbus Pharmaceuticals

11

Mid-Stage Scleroderma Products (Phase II)

11.1

EHP 101: Emerald Health Pharmaceuticals

12

Early Stage Scleroderma Products (Phase I)

12.1

VIB7734: Viela Bio

13

Pre-clinical and Discovery Stage Scleroderma Products

13.1

LMY-920: Luminary Therapeutics

14

Inactive Scleroderma Pipeline Products 

15

Key Scleroderma Products

16

Unmet Needs

17

Scleroderma Market Drivers and Barriers

18

Future Perspectives and Conclusion

19

Analyst Views

20

Key Scleroderma Companies

21

Appendix

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.  Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

For more insights, visit Pharma, Healthcare, and Biotech News 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/scleroderma-pipeline-insight

Related Articles